Granata Bio Announces Initial Pregnancies in GRACE Study
Pregnancies represent an important milestone for GB-hMG program
Duxbury, MA — May 6, 2026 — Granata Bio Corporation, a biopharmaceutical company focused exclusively on reproductive health, today announce the first pregnancies in the GRACE study evaluating Granata Bio Human Menopausal Gonadotropin (GB-hMG).
Gonadotropins, including GB-hMG, are a well-established component of IVF protocols, supporting follicular development and progression to pregnancy. The pregnancies observed in the ongoing GRACE investigational study represent an important milestone for the GB-hMG program.
“These first pregnancies in the GRACE study support the clinical potential of GB-hMG within routine IVF practice,” said John Frattarelli, MD, HCLD, Medical, Practice and Laboratory Director at the Fertility Institute of Hawaii and a GRACE Study Investigator. “These early outcomes are encouraging; continued enrollment and follow-up will be important to fully evaluate the study results.”
Granata Bio’s mission is to reshape the future of infertility treatment by bringing innovation back to reproductive health and expanding therapeutic choices for patients on a path to parenthood.
“These early pregnancies represent an important clinical milestone for the GB-hMG program,” said Sarah Faranda, Chief Development Officer of Granata Bio. “We are especially encouraged to see patients progressing toward their goal of building families.”
“The progress we are seeing in GRACE reflects our development philosophy at Granata Bio: disciplined execution, close collaboration with investigators, and a focus on generating clinically meaningful and regulatory-relevant evidence. We look forward to completing the study and generating a comprehensive data set to define the role of GB-hMG in ART.”
The GRACE investigational study remains ongoing, with recruitment continuing for women ages 35-42 (NCT07216742).
About the GRACE Study
The GRACE investigational study is a multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of GB-hMG in the development of multiple follicles, pregnancy and cumulative live birth as part of an assisted reproductive technology (ART) cycle in women. c. The study is being conducted at fertility clinics across the United States. To learn more or to find a participating IVF clinic near you, please visit GraceIVFStudy.com.
About Granata Bio
Granata Bio Corporation is a biopharmaceutical company focused exclusively on reproductive health, dedicated to reimagining what’s possible to help build families. Founded in 2018, the company develops and accelerates fertility treatments that expand therapeutic choices and improve access and affordability. Backed by deep fertility expertise, strategic partnerships, and a growing pipeline, Granata Bio is advancing innovation across reproductive medicine.
Media Contact:
mediarelations@granata.bio
Forward‑Looking Statements
This press release contains forward‑looking statements, including statements regarding the progress, potential outcomes, and anticipated significance of the GRACE study and related development programs. Forward‑looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, but are not limited to, clinical trial enrollment and execution, variability in clinical outcomes, regulatory review, and other factors inherent in the development of biopharmaceutical products. Granata Bio undertakes no obligation to update or revise these forward‑looking statements to reflect events or circumstances after the date of this release.